- LC–MS/MS Method for Simultaneous Determination of Famitinib and its Major Metabolites in Human Plasma
Shiyi Liu et al, 2018, Bioanalysis CrossRef - Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells
Mi Zhang et al, 2021, Thoracic Cancer CrossRef - Combinational therapies for the treatment of advanced cervical cancer
Alfonso Duenas-Gonzalez, 2023, Expert Opinion on Pharmacotherapy CrossRef - Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?
Aini Hyytiäinen et al, 2021, Frontiers in Oncology CrossRef - The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
Ting Li et al, 2022, Cancer Chemotherapy and Pharmacology CrossRef - Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging)
Chen Huang et al, 2024, Current Drug Delivery CrossRef - CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study
Yunzhe Huang et al, 2023, Expert Opinion on Drug Metabolism & Toxicology CrossRef - The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
Massimiliano Salati et al, 2021, Cancer Management and Research CrossRef - Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects
Linlin Hu et al, 2022, Investigational New Drugs CrossRef